Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$3.17 - $6.17 $35,754 - $69,591
-11,279 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$4.16 - $13.72 $46,920 - $154,747
11,279 New
11,279 $61,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Halbert Hargrove Global Advisors, LLC Portfolio

Follow Halbert Hargrove Global Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Halbert Hargrove Global Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Halbert Hargrove Global Advisors, LLC with notifications on news.